SunS, I doubt Drs. Wolchok & Merghoub and the rest of the Mem. Sloan Wolchok Lab throw around the phrase “Eliminates Advanced Tumors” just any ‘ol place, for any ‘ol reason, in their presentations. We’ll know a lot more on March 1st at ~4:30pmET.
#2: AACR’17(4-3-17) http://tinyurl.com/jxfm3hb 4-3-17/8am #1651 - Session: TUMOR MICROENVIRONMENT & CHECKPOINTS “Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model” Daniel Hirschhorn-Cymerman 1, Sara Sara Schad 1, Sadna Budhu 1, Zhong Hong 1, Xia Yang 1, Jeff Hutchins 2, Bruce Freimark 2, Michael Gray 2, Jedd Wolchok 1, Taha Merghoub [Memorial Sloan Kettering] 1=Memorial Sloan Kettering CC, NYC [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ] 2=Peregrine Pharmaceuticals ***FULL ABSTRACTS TO PUB. AT AACR.COM 3-1-17.
“Adoptive Cell Transfer (ACT)” is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system, with the goal of improving immune functionality and characteristics. In cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient.
"...Second, the Immunotherapy Dream Team is pursuing multiple Adoptive Cell Transfer (ACT) approaches, which increase immunity.” DREAM TEAM LEADERSHIP: 10 scientists, incl. MSKCC’s Jedd D. Wolchok & Michel Sadelain. http://parker.org/initiatives/immunotherapy
Market Data 
Markets 
AI
